Research Article: RET fusion driven (RETfus+) non-small cell lung cancer: a comprehensive genomic profiling study with histologic correlation
Abstract:
Background: Fusion of the RET gene resulting in clinically significant Genomic Alteration (GA) occur in 1-2% of NSCLC in the United States and has emerged as a major target for RET inhibitors which are first line treatment options in the Stage 4 setting. RET fusions have also been well-described as acquired resistance mutations in cases of EGFR-driven NSCLC treated with anti-EGFR tyrosine kinase inhibitors including erlotinib and osimertinib. The aim of this study was to determine whether RET fusion positive (RETfus+) NSCLC represents a unique histologic subtype of the disease with a unique genomic profile.
No summary available.